Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) launched an updated Sancuso website on March 17, 2026, offering educational resources for chemotherapy-induced nausea and vomiting (CINV).

The site highlights Sancuso as the only prescription granisetron transdermal patch approved by the FDA to prevent CINV for up to five days, and includes clinical data, HCP tools, patient education, and prescribing information.

News Market Reaction – CPIX

-1.63%

5 alerts

-1.63% News Effect

+5.1% Peak in 1 hr 4 min

-$838K Valuation Impact

$51M Market Cap

0.1x Rel. Volume

On the day this news was published, CPIX declined 1.63%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $838K from the company's valuation, bringing the market cap to $51M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patch duration: up to five days Application timing: 24 to 48 hours before chemotherapy Regimen coverage: up to five consecutive days +1 more

4 metrics

Patch duration up to five days Sancuso delivers continuous medication through the skin

Application timing 24 to 48 hours before chemotherapy Sancuso patch application window prior to chemotherapy

Regimen coverage up to five consecutive days CINV prevention duration for chemotherapy regimens

Trial phase Phase II Ifetroban clinical programs for multiple indications

Market Reality Check

Price: $3.01 Vol: Volume 28,674 is at 0.21x...

low vol

$3.01 Last Close

Volume Volume 28,674 is at 0.21x the 20-day average of 134,696, indicating relatively muted activity. low

Technical Shares at 3.06 are trading below the 200-day MA of 3.55, reflecting a weaker longer-term trend.

Peers on Argus

CPIX showed a 0.66% change with only one peer (CTOR) in momentum scanners, up 2....

1 Up

CPIX showed a 0.66% change with only one peer (CTOR) in momentum scanners, up 2.979999966919422% and without news. Broader specialty pharma peers show mixed moves, suggesting this update is more company-specific than sector-driven.

Historical Context

5 past events · Latest: Mar 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 04	Market outlook note	Positive	-4.1%	Forecast of strong long‑term H. pylori market growth and evolving therapies.
Mar 03	Earnings report	Positive	-19.9%	Reported double‑digit Q4 and full‑year 2025 revenue growth with better profitability.
Feb 25	Product promotion	Positive	+4.6%	Launch of national U.S. sales promotion for Talicia with co‑commercialization partner.
Feb 25	JV commercialization	Positive	+4.6%	Start of joint U.S. sales and operations for Talicia via Talicia Holdings entity.
Feb 24	Earnings date set	Neutral	+4.6%	Announcement of timing for 2025 annual results and company update call.

Pattern Detected

Recent history shows several fundamentally positive announcements where shares moved lower afterward, alongside some aligned positive reactions to commercialization news.

Recent Company History

Over the last few weeks, Cumberland reported strong Q4 2025 and full‑year 2025 revenue growth, narrowing its annual net loss and improving cash generation. Commercial traction around Talicia intensified with a national U.S. promotion launch and a joint U.S. commercialization structure. Market commentary also highlighted long‑term growth prospects in the H. pylori segment. Ahead of these results, the company flagged its diversified hospital, gastroenterology and oncology portfolio. Today’s Sancuso website launch fits into this ongoing commercial execution and brand‑building across its oncology franchise.

Market Pulse Summary

This announcement highlights Cumberland’s focus on strengthening its oncology supportive‑care franch...

Analysis

This announcement highlights Cumberland’s focus on strengthening its oncology supportive‑care franchise by enhancing digital education and access around Sancuso. The new website emphasizes CINV prevention, patient resources, and expert guidance, complementing the company’s broader portfolio of FDA‑approved hospital, gastroenterology and oncology brands. In light of recent revenue growth and expanded commercialization efforts, investors may watch how Sancuso usage trends, future label or access changes, and progress in ifetroban’s Phase II programs influence the overall growth profile.

Key Terms

chemotherapy-induced nausea and vomiting, CINV, transdermal patch, antiemetic therapy, +4 more

8 terms

chemotherapy-induced nausea and vomiting medical

"resources, clinical information and expert insights related to the prevention of chemotherapy-induced nausea and vomiting (CINV)"

Chemotherapy-induced nausea and vomiting is the upset stomach and vomiting that many patients experience as a side effect of cancer drugs; think of it as severe motion sickness caused by treatment rather than by travel. It matters to investors because the condition affects how well patients can stay on therapy, drives additional medical visits and supportive-care spending, and creates demand for anti-nausea drugs and services—factors that influence healthcare costs, drug sales and clinical trial outcomes.

CINV medical

"information and expert insights related to the prevention of chemotherapy-induced nausea and vomiting (CINV)"

Chemotherapy-induced nausea and vomiting (CINV) is the nausea and vomiting patients experience as a side effect of cancer chemotherapy. It matters to investors because drugs or devices that prevent or treat CINV can become widely used supportive-care products, driving sales, shaping competitive positions and affecting regulatory and reimbursement outcomes; think of them as motion-sickness remedies for people undergoing chemo, where a reliable solution can change prescribing and market dynamics.

transdermal patch medical

"Sancuso is the first and only prescription granisetron transdermal patch approved for the prevention"

A transdermal patch is a thin, adhesive strip applied to the skin that steadily releases a drug through the skin into the bloodstream, like a sticky bandage that delivers medicine over time. For investors, patches matter because they can improve patient convenience and consistency of dosing, extend patent life or product differentiation, and affect regulatory, manufacturing and market potential compared with pills or injections.

antiemetic therapy medical

"guidance on CINV management and antiemetic therapy in oncology patients"

Antiemetic therapy is the use of medicines or treatments designed to prevent or stop nausea and vomiting. Investors care because these therapies can improve patient comfort and adherence to other medical treatments (like chemotherapy or surgery), affect market demand and reimbursement, and influence a drug or device maker’s regulatory approvals and sales potential—think of them as the shock absorbers that keep a larger treatment plan on track.

oncology medical

"antiemetic therapy in oncology patients"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

FDA regulatory

"Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

Duchenne Muscular Dystrophy medical

"ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy"

A rare, inherited condition that progressively weakens muscles, Duchenne muscular dystrophy causes the body’s muscle fibers to break down over time, often leading to severe disability. For investors, it matters because the small, well-defined patient population, high unmet medical need and complex regulatory and pricing dynamics mean successes or failures in clinical trials, approvals, or therapies can have outsized effects on a company’s valuation and future revenue prospects.

Idiopathic Pulmonary Fibrosis medical

"ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

AI-generated analysis. Not financial advice.

Sancuso – the Difference Between Life and Living

NASHVILLE, Tenn., March 17, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso^® (granisetron transdermal system) website. The website is designed to provide health care professionals and patients with enhanced access to educational resources, clinical information and expert insights related to the prevention of chemotherapy-induced nausea and vomiting (CINV). The website also features the brand's key message: "Sancuso – the Difference between Life and Living."

Sancuso is the first and only prescription granisetron transdermal patch approved for the prevention of chemotherapy-induced nausea and vomiting, delivering continuous medication through the skin for up to five days. The patch provides an alternative to oral antiemetic therapy and may help support patients who experience difficulty taking or retaining oral medications during chemotherapy treatment.

Key features of the new Sancuso website include:

• Comprehensive Product Information:
  Detailed overview of Sancuso, including clinical data, prescribing information and guidance on appropriate patient use for CINV prevention during chemotherapy.
• Healthcare Provider Resources:
  Educational tools designed to support oncologists and oncology care teams in managing CINV.
• Physician Insights Resource Center: 
  A dedicated section featuring expert perspectives and clinical insights from Dr. Ehsan, MD, PhD, providing practical guidance on CINV management and antiemetic therapy in oncology patients.
• Patient Education: 
  Information to help patients better understand nausea and vomiting associated with chemotherapy and the available treatment options.
• Enhanced Website Experience: 
  Simplified navigation and mobile-optimized design to ensure users can quickly find relevant information about CINV prevention and oncology supportive care.

Healthcare professionals and patients can explore the updated SANCUSO website and educational resources at www.sancuso.com, which also provides full prescribing and safety information.

About Sancuso^® (granisetron) Transdermal System
Sancuso is the only skin patch approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and/or highly emetogenic chemotherapy. When applied 24 to 48 hours before receiving chemotherapy, the Sancuso patch slowly and continuously releases the medicine contained in the adhesive through clean and intact skin areas into the patient's bloodstream. It can prevent CINV for chemotherapy regimens of up to five consecutive days. For full prescribing and safety information, visit www.sancuso.com.

About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes:

• Acetadote^® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
• Caldolor^® (ibuprofen) injection, for the treatment of pain and fever;
• Kristalose^® (lactulose) oral, a prescription laxative, for the treatment of constipation;
• Sancuso^® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
• Vaprisol^® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia;
• Vibativ^® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections, and
• Talicia^®(omeprazole magnesium, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection.

The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis.

Forward-Looking Statements
This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-launches-new-sancuso-website-featuring-educational-resources-for-chemotherapy-induced-nausea-and-vomiting-302715562.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

What did Cumberland Pharmaceuticals (CPIX) announce on March 17, 2026 about Sancuso?

They launched an updated Sancuso website with expanded educational resources and prescribing details. According to Cumberland Pharmaceuticals, the site centralizes clinical data, healthcare provider tools, patient education, expert insights, and full prescribing and safety information for Sancuso.

How does the Sancuso transdermal patch work and what is its approved duration (CPIX)?

Sancuso delivers granisetron through the skin for continuous release up to five days when applied before chemotherapy. According to Cumberland Pharmaceuticals, apply the patch 24–48 hours before chemotherapy to prevent nausea and vomiting during regimens up to five consecutive days.

What resources does the new Sancuso website provide for oncology healthcare professionals (CPIX)?

The site offers clinical data, prescribing information, and educational tools for managing CINV in oncology patients. According to Cumberland Pharmaceuticals, it includes a Physician Insights Resource Center with expert perspectives to support antiemetic therapy decisions in clinical practice.

Can patients find safety and usage information for Sancuso on the new website (CPIX)?

Yes, the updated site contains patient education, usage guidance, and full safety and prescribing information for Sancuso. According to Cumberland Pharmaceuticals, the content explains patch application, expected benefits, and considerations for patients receiving moderately or highly emetogenic chemotherapy.

Where can clinicians and patients access the new Sancuso educational materials from Cumberland Pharmaceuticals (CPIX)?

All resources are available at www.sancuso.com, including prescribing and safety information. According to Cumberland Pharmaceuticals, the site is mobile-optimized with simplified navigation to help users quickly locate clinical guidance and patient-facing materials.